Syncom Formulations (India) Limited (SYNCOMF.BO)
INR 16.66
(3.29%)
INR 16.66
(3.29%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 430.27 Million INR | -13.11% |
| 2022 | 341.47 Million INR | 6.92% |
| 2021 | 319.59 Million INR | -28.77% |
| 2020 | 450.31 Million INR | 104.11% |
| 2019 | 218.76 Million INR | 29.9% |
| 2018 | 169.23 Million INR | 5.57% |
| 2017 | 159.59 Million INR | -17.65% |
| 2016 | 194.52 Million INR | 0.84% |
| 2015 | 192.35 Million INR | -4.3% |
| 2014 | 192.79 Million INR | 16.0% |
| 2013 | 173.55 Million INR | 63.15% |
| 2012 | 106.4 Million INR | 23.82% |
| 2011 | 85.93 Million INR | 160.87% |
| 2010 | 32.94 Million INR | -65.55% |
| 2009 | 95.61 Million INR | 27.87% |
| 2008 | 74.77 Million INR | -4.13% |
| 2007 | 77.99 Million INR | -7.73% |
| 2006 | 84.53 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 104.54 Million INR | -5.83% |
| 2023 Q4 | 94.24 Million INR | -20.89% |
| 2023 Q3 | 119.12 Million INR | 14.5% |
| 2023 Q2 | 104.03 Million INR | 24.83% |
| 2023 Q1 | 83.34 Million INR | -33.97% |
| 2023 FY | - INR | -13.11% |
| 2022 Q1 | 64.66 Million INR | -13.55% |
| 2022 FY | - INR | 6.92% |
| 2022 Q4 | 126.21 Million INR | 60.09% |
| 2022 Q3 | 78.83 Million INR | 10.19% |
| 2022 Q2 | 71.55 Million INR | 10.65% |
| 2021 Q4 | 74.8 Million INR | 4.84% |
| 2021 Q2 | 83.94 Million INR | 0.78% |
| 2021 Q3 | 71.34 Million INR | -15.01% |
| 2021 FY | - INR | -28.77% |
| 2021 Q1 | 83.29 Million INR | -30.37% |
| 2020 Q3 | 142.38 Million INR | 4.86% |
| 2020 Q4 | 119.61 Million INR | -15.99% |
| 2020 FY | - INR | 104.11% |
| 2020 Q1 | 50.2 Million INR | -2.62% |
| 2020 Q2 | 135.78 Million INR | 170.47% |
| 2019 Q4 | 51.55 Million INR | -7.65% |
| 2019 Q1 | 51.37 Million INR | 21.43% |
| 2019 Q2 | 59.86 Million INR | 16.52% |
| 2019 Q3 | 55.82 Million INR | -6.76% |
| 2019 FY | - INR | 29.9% |
| 2018 Q1 | 29.59 Million INR | -14.48% |
| 2018 FY | - INR | 5.57% |
| 2018 Q4 | 42.31 Million INR | -13.19% |
| 2018 Q3 | 48.74 Million INR | 0.86% |
| 2018 Q2 | 48.32 Million INR | 63.3% |
| 2017 Q2 | 38.01 Million INR | -7.42% |
| 2017 FY | - INR | -17.65% |
| 2017 Q4 | 34.6 Million INR | -27.04% |
| 2017 Q3 | 47.43 Million INR | 24.76% |
| 2017 Q1 | 41.06 Million INR | 4.0% |
| 2016 Q1 | 46.98 Million INR | 10.17% |
| 2016 FY | - INR | 0.84% |
| 2016 Q4 | 39.48 Million INR | 0.0% |
| 2015 Q3 | 54.89 Million INR | -5.88% |
| 2015 Q1 | 36.85 Million INR | -35.87% |
| 2015 Q2 | 58.31 Million INR | 58.22% |
| 2015 FY | - INR | -4.3% |
| 2015 Q4 | 42.65 Million INR | -22.3% |
| 2014 Q3 | 61.51 Million INR | 16.09% |
| 2014 Q1 | 29.39 Million INR | -29.58% |
| 2014 Q2 | 52.98 Million INR | 80.23% |
| 2014 FY | - INR | 16.0% |
| 2014 Q4 | 57.47 Million INR | -6.56% |
| 2013 Q2 | 40.56 Million INR | 29.69% |
| 2013 Q4 | 41.74 Million INR | -14.53% |
| 2013 FY | - INR | 63.15% |
| 2013 Q1 | 31.27 Million INR | 42.82% |
| 2013 Q3 | 48.84 Million INR | 20.42% |
| 2012 Q4 | 21.89 Million INR | -46.7% |
| 2012 Q2 | 35.23 Million INR | 306.07% |
| 2012 Q3 | 41.08 Million INR | 16.59% |
| 2012 Q1 | 8.67 Million INR | 0.0% |
| 2012 FY | - INR | 23.82% |
| 2011 FY | - INR | 160.87% |
| 2010 FY | - INR | -65.55% |
| 2009 FY | - INR | 27.87% |
| 2008 FY | - INR | -4.13% |
| 2007 FY | - INR | -7.73% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 95.526% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.304% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 93.73% |
| Granules India Limited | 8.6 Billion INR | 94.999% |
| Indoco Remedies Limited | 2.64 Billion INR | 83.745% |
| Achyut Healthcare Limited | 524 Thousand INR | -82013.74% |
| Ajanta Pharma Limited | 12.56 Billion INR | 96.576% |
| Alkem Laboratories Limited | 24.19 Billion INR | 98.222% |
| Alpa Laboratories Limited | 86.12 Million INR | -399.583% |
| Brooks Laboratories Limited | 41.72 Million INR | -931.145% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 81.743% |
| Bajaj HealthCare Limited | 444.51 Million INR | 3.203% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 70.908% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.513% |
| Eris Lifesciences Limited | 6.98 Billion INR | 93.841% |
| FDC Limited | 4.4 Billion INR | 90.225% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 96.207% |
| Gufic Biosciences Limited | 1.48 Billion INR | 70.937% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 93.729% |
| Ipca Laboratories Limited | 13.29 Billion INR | 96.765% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -33.023% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 620.116% |
| Lasa Supergenerics Limited | -65.08 Million INR | 761.149% |
| Laurus Labs Limited | 8 Billion INR | 94.626% |
| Lupin Limited | 36.96 Billion INR | 98.836% |
| Mankind Pharma Limited | 28.09 Billion INR | 98.468% |
| Medicamen Biotech Limited | 245.66 Million INR | -75.151% |
| Medico Remedies Limited | 150.37 Million INR | -186.13% |
| Megasoft Limited | 284.73 Million INR | -51.117% |
| NATCO Pharma Limited | 18.79 Billion INR | 97.711% |
| Piramal Pharma Limited | 13.05 Billion INR | 96.704% |
| RPG Life Sciences Limited | 1.28 Billion INR | 66.424% |
| Sigachi Industries Limited | 883.39 Million INR | 51.293% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.689% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 90.801% |
| Unichem Laboratories Limited | 742.35 Million INR | 42.039% |
| Wanbury Limited | 985.49 Million INR | 56.339% |
| Windlas Biotech Limited | 781.72 Million INR | 44.958% |
| ZIM Laboratories Limited | 462.09 Million INR | 6.886% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 99.235% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 111.532% |
| Divi's Laboratories Limited | 25.43 Billion INR | 98.308% |
| Hester Biosciences Limited | 539.47 Million INR | 20.241% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 85.726% |
| Amrutanjan Health Care Limited | 682.53 Million INR | 36.959% |
| Bal Pharma Limited | 345.59 Million INR | -24.504% |
| Strides Pharma Science Limited | 3.76 Billion INR | 88.571% |
| Venus Remedies Limited | 711.8 Million INR | 39.551% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 88.994% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 72.485% |
| Shilpa Medicare Limited | 2.58 Billion INR | 83.374% |
| Aarti Drugs Limited | 3.24 Billion INR | 86.755% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 83.493% |
| Suven Life Sciences Limited | -992.78 Million INR | 143.341% |
| Ind-Swift Limited | 1.06 Billion INR | 59.601% |
| Valiant Laboratories Limited | 12.73 Million INR | -3277.628% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 95.391% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 115.248% |
| Themis Medicare Limited | 562.6 Million INR | 23.521% |
| Hikal Limited | 2.69 Billion INR | 84.018% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 98.771% |
| Sequent Scientific Limited | 549.8 Million INR | 21.74% |
| Novartis India Limited | 1.26 Billion INR | 66.101% |
| Wockhardt Limited | 1.08 Billion INR | 60.16% |
| Jubilant Pharmova Limited | 8 Billion INR | 94.626% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -3194.105% |
| Neuland Laboratories Limited | 4.74 Billion INR | 90.938% |
| Morepen Laboratories Limited | 1.72 Billion INR | 75.07% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -49.7% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -145.948% |